Results 61 to 70 of about 749,314 (382)

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley   +1 more source

Comparative analysis of blood lymphocytes of patients with acute and chronic myeloid leukemia by surface and intracellular α1-acid glycoprotein and fibronectin

Біологічні студії, 2014
The exposition of α1-acid glycoprotein and fibronectin on the surface and inside the lymphocytes of healthy donors and hematological patients with acute and chronic myeloid leukemia were studied.
G. S. Маslak
doaj   +1 more source

Entropy of leukemia on multidimensional morphological and molecular landscapes [PDF]

Phys. Rev. X 4, 021038 (2014), 2014
Leukemia epitomizes the class of highly complex diseases that new technologies aim to tackle by using large sets of single-cell level information. Achieving such goal depends critically not only on experimental techniques but also on approaches to interpret the data.
arxiv   +1 more source

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia

Science, 2020
Taking preventive measures Recent technological advances have made it possible to detect, in healthy individuals, premalignant blood cells that are likely to progress to hematologic cancer.
H. Uckelmann, Stephanie M. Kim, E. Wong, C. Hatton, H. Giovinazzo, Jayant Y. Gadrey, A. Krivtsov, F. Rücker, K. Döhner, G. McGeehan, R. Levine, L. Bullinger, G. Vassiliou, S. Armstrong   +13 more
semanticscholar   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Functional Genomic Landscape of Acute Myeloid Leukemia

Nature, 2018
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events.
J. Tyner, C. Tognon, D. Bottomly, Beth Wilmot, S. Kurtz, S. Savage, Nicola Long, Anna Reister Schultz, E. Traer, Melissa L. Abel, A. Agarwal, A. Blucher, U. Borate, Jade Bryant, Russell T. Burke, A. Carlos, Richie Carpenter, J. Carroll, B. Chang, Cody Coblentz, Amanda d’Almeida, R. Cook, A. Danilov, K. Dao, Michie Degnin, D. Devine, J. Dibb, David K Edwards, C. Eide, I. English, J. Glover, Rachel Henson, Hibery Ho, Abdusebur Jemal, Kara Johnson, Ryan C. Johnson, Brian Junio, A. Kaempf, Jessica T. Leonard, Chen-Jzong Lin, S. Liu, Pierrette Lo, M. Loriaux, Samuel B. Luty, T. Macey, Jason D. MacManiman, Jacqueline Martinez, M. Mori, D. Nelson, Ceilidh Nichols, Jill Peters, Justin W Ramsdill, Angela Rofelty, R. Schuff, R. Searles, E. Segerdell, Rebecca Smith, S. Spurgeon, Tyler Sweeney, Aashis Thapa, Corinne Visser, Jacob P. Wagner, Kevin Watanabe-Smith, Kristen Werth, Joelle Wolf, Libbey White, Amy Yates, Haijiao Zhang, C. Cogle, R. Collins, D. Connolly, M. Deininger, L. Drusbosky, C. Hourigan, C. Jordan, P. Kropf, Tara L. Lin, Micaela E. Martinez, B. Medeiros, Rachel R. Pallapati, D. Pollyea, R. Swords, J. Watts, S. Weir, D. Wiest, R. M. Winters, S. McWeeney, B. Druker   +87 more
semanticscholar   +1 more source

Progress in Acute Myeloid Leukemia [PDF]

Clinical Lymphoma Myeloma and Leukemia, 2015
Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age ...
Kadia, Tapan M, Ravandi, Farhad, O'Brien, Susan, Cortes, Jorge, Kantarjian, Hagop M   +4 more
openaire   +4 more sources

Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

Molecular Oncology, EarlyView.
Adaptive ERK reactivation hinders FLT3 tyrosine kinase inhibitor (TKI) treatment in FLT3/ITD acute myeloid leukemia. Here, we report that FLT3 TKI treatment rapidly induces AXL expression and upregulation that is temporally associated with the adaptive ERK reactivation.
Tessa S. Seale, Li Li, J. Kyle Bruner, Melody Chou, Bao Nguyen, Jaesung Seo, Ruiqi Zhu, Mark J. Levis, Christine A. Pratilas, Donald Small   +9 more
wiley   +1 more source

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Haematologica, 2018
Allogeneic hematopoietic stem cell transplantation is the optimal care for patients with high-risk or intermediate - acute myeloid leukemia. In patients lacking matched sibling donor, haploidentical donors are an option.
Dalila Salvatore, Myriam Labopin, Annalisa Ruggeri, Giorgia Battipaglia, Ardeshir Ghavamzadeh, Fabio Ciceri, Didier Blaise, William Arcese, Gerard Sociè, Jean Henri Bourhis, Maria Teresa Van Lint, Benedetto Bruno, Anne Huynh, Stella Santarone, Eric Deconinck, Mohamad Mohty, Arnon Nagler   +16 more
doaj   +1 more source

Early Risk Prediction of Chronic Myeloid Leukemia with Protein Sequences using Machine Learning-based Meta-Ensemble [PDF]

arXiv, 2023
Leukemia, the cancer of blood cells, originates in the blood-forming cells of the bone marrow. In Chronic Myeloid Leukemia (CML) conditions, the cells partially become mature that look like normal white blood cells but do not resist infection effectively.
arxiv